insight
Energy & Resources
insight
Energy & Resources
insight
Energy & Resources
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Mendus
Mendus is an immuno-oncology company focused on immunotherapies for myeloid blood cancers. The company’s leading clinical candidate is vididencel, an off-the-shelf cellular immunotherapy that has demonstrated durable clinical remissions in acute myeloid leukemia (AML). Mendus is developing vididencel as a broadly applicable post-remission treatment in AML and has expanded indications to include chronic myeloid leukemia (CML). Earlier-stage programs focusing on ovarian cancer and other solid tumors.
Mendus — 13 videos in collection
Erik Manting, CEO of Mendus, catches up with Arron Aatkar, director at Edison, after their recent interview in London. Here, they discuss the latest Sellas Phase III readout in acute myeloid leukaemia (AML), how this validates immunotherapy as an approach in this indication and what it means for Mendus’s lead product vididencel.
Get access to the very latest content matched to your personal investment style.